Diabetes and obesity Diabetes and obesity
Conditions
Interventions
There is no intervention. This is an observational study using retrospectively collected routine care data. Exposure consists of GLP-1RA use, compared with other antihyperglycaemic (such as SGLT-2 inh
Sponsors
Radboud Universitair Medisch Centrum
Eligibility
Inclusion criteria
Inclusion criteria: Any individual with T2DM and/or obesity who starts a GLP-1RA, sulphonylurea, DPP-4 inhibitor, SGLT-2 inhibitor or non-GLP-1RA anti-obesity agent (new prescription).
Exclusion criteria
Exclusion criteria: Age < 18 years at cohort entryPregnancy at any moment during the follow-upPatients who switched between GLP-1RA type during the follow-up
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in cardiometabolic parameters (HbA1c, body weight/BMI, blood pressure, lipid profile, renal function).Infectious disease outcomes: hospitalisation, ICU admission and mortality.Incidence of autoimmune/inflammatory diseases. | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in use of co-medication, such as antihypertensive, lipid-lowering and glucose-lowering drugs after initiation of GLP-1RA.Differences in effectiveness between different GLP-1RA formulations, including subcutaneous versus oral semaglutide.Effects of combination therapy (GLP-1RA plus SGLT-2 inhibitor) compared with monotherapy on cardiometabolic outcomes.Prescription patterns, including initiation strategies, up-titration schedules and reasons for discontinuation.Frequency and nature of adverse effects, particularly gastrointestinal side effects.Associations between GLP-1RA use and substance use behaviours, such as alcohol consumption and smoking (exploratory). | — |
Countries
Netherlands
Contacts
Public ContactM.M. Smits
Radboud Universitair Medisch Centrum
Outcome results
None listed